Visual quality after implantation of bioanalogic intraocular lens in cataract patients: 3 months results from international observational registry
(results will display both Free Papers & Poster)
Session Details
Session Title: Pseudophakic IOLs: Multifocal & Accommodative
Session Date/Time: Monday 07/09/2015 | 08:00-10:30
Paper Time: 10:12
Venue: Room 1
First Author: : E.Mrukwa-Kominek POLAND
Co Author(s): : R. Ang M. Ilavska L. Hans C. Lenis
Abstract Details
Purpose:
Clinical evaluation of functional results and quality of vision after bilateral implantation of a bioanalogic, polyfocal, accommodative intraocular lens.
Setting:
Department of Ophthalmology, Silesian University of Medicine, Katowice, Poland
Methods:
A prospective, international, multicenter case study comprised 126 eyes of 63 patients treated due to cataract and presbyopia who underwent phacoemulsification followed by WIOL-CF (Medicem) implantation. Follow-up was 3 months after surgery of the second eye. Binocular and monocular visual acuity for distance, intermediate and near vision (reading table), subjective refraction, glare and halos rate analysis, PCO, depth of focus and overall satisfaction of patients were analyzed.
Results:
63 cataract patients, mean age 61.9±10.6 year, were implanted with bioanalogic intraocular lens WIOL-CF. Mean post-operative UCDVA was 0.96±0.14 decimal. Mean UCNVA was 0.24±0.15 logMAR. Only 5% of patients reported moderate glare/halo, 95% of patients were spectacle independent for daily activities, driving and reading, 98% were satisfied or very satisfied. Postoperative improvement in UCDVA, BCDVA, UCNVA in comparison to preop value were observed in 98% of eyes.
Conclusions:
The implantation of polyfocal, bioanalogic intraocular lens is interesting option for patients who wants to be totally independent of glasses after cataract surgery. WIOL-CF brings back full, natural vision via combination of multiple mechanisms of action, that are similar to those of natural crystalline lens.
Financial Interest:
One of the authors travel has been funded, fully or partially, by a competing company